VuBru, why no one is talking about what AVII found in that Epanova trial death rate in the treatment arm was lower for a 2 or 3 gm equivalent of EPA content? I think it is very important this board pay attention to that finding. AVII is very confident R-It trial results will show V reduces cardio related deaths. AVII posted here a couple of days ago.
If we need 5.2% just to hit the minimum target there's not much wiggle room. Original design was 5.9% placebo rate, but that dropped to as low as 5.2% when they added the extra 1000 patients.
With the trial extending into 2018 let's hope the slow down in events is due to Vascepa and not a lower p-rate.
News 
Market Data 
Discover 
